Case Report: Robust and durable response to the combination of tislelizumab and chemotherapy in advanced thymic epithelial tumors: a case series

Case Report: Robust and durable response to the combination of tislelizumab and chemotherapy in advanced thymic epithelial tumors: a case series

BackgroundThymic epithelial tumors (TETs), categorized predominantly as thymoma (T) or thymic carcinoma (TC), face a challenging prognosis and limited treatment options. Although chemotherapy remains the established treatment for advanced TETs, its responses tend to be short-lived. The emergence of...

Full description

Saved in:
Bibliographic Details
Main Authors: Lantian Zhang, Yuqi Zhang, Shuke Li, Yan Wang, Yue Yu, Jing He, Wen Gao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
tislelizumab
immunotherapy
thymoma
thymic carcinoma
first-line treatment
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1516297/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items